Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 305

1.

Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors.

Jackson LA, Austin G, Chen RT, Stout R, DeStefano F, Gorse GJ, Newman FK, Yu O, Weniger BG; Vaccine Safety Datalink Study Group.

Vaccine. 2001 Sep 14;19(32):4703-9.

PMID:
11535320
2.

Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.

Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, Campbell JD, Levine MM.

Vaccine. 2011 Nov 28;29(51):9544-50. doi: 10.1016/j.vaccine.2011.09.097. Epub 2011 Oct 8.

PMID:
21986218
3.

Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.

Mitchell DK, Ruben FL, Gravenstein S.

Pediatr Infect Dis J. 2005 Oct;24(10):925-7.

PMID:
16220095
4.

Dose sparing with intradermal injection of influenza vaccine.

Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM.

N Engl J Med. 2004 Nov 25;351(22):2295-301. Epub 2004 Nov 3.

5.

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

Squarcione S, Sgricia S, Biasio LR, Perinetti E.

Vaccine. 2003 Mar 7;21(11-12):1268-74.

PMID:
12559808
6.

Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?

Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.

Pediatrics. 2006 Sep;118(3):e570-8.

PMID:
16950948
7.

Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial.

McAllister L, Anderson J, Werth K, Cho I, Copeland K, Le Cam Bouveret N, Plant D, Mendelman PM, Cobb DK.

Lancet. 2014 Aug 23;384(9944):674-81. doi: 10.1016/S0140-6736(14)60524-9. Epub 2014 May 31.

PMID:
24881803
8.

Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.

Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.

J Infect Dis. 2006 Oct 15;194(8):1032-9. Epub 2006 Sep 11.

PMID:
16991077
9.

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B; CAIV-T Asthma Study Group.

Pediatr Infect Dis J. 2006 Oct;25(10):860-9.

PMID:
17006278
10.

Safety and immunogenicity of a paediatric presentation of an influenza vaccine.

Gonzalez M, Pirez MC, Ward E, Dibarboure H, García A, Picolet H.

Arch Dis Child. 2000 Dec;83(6):488-91.

11.

Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.

Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M.

Hum Vaccin. 2005 Jan-Feb;1(1):37-42. Epub 2005 Jan 12.

PMID:
17038827
12.
13.

[Study of reactogenicity, safety and immunogenicity of inactivated virosomal split influenza vaccine "Grifor" during phase I clinical trial].

Zverev VV, Korovkin SA, Mironov AN, Mel'nikov SIa, Mikhaĭlova NA, Kostinov MP, Dyldina NV, Zhirova SN.

Zh Mikrobiol Epidemiol Immunobiol. 2009 Jan-Feb;(1):26-31. Russian.

PMID:
19338233
14.

[An immunogenicity and reactogenicity study of a purified, inactivated trivalent influenza vaccine for parenteral administration prepared for the 1996-1997 season].

Lupulescu E, Ioniţă E, Botez D, Matepciuc M, Tabra ME, Tecu C, Alexandrescu V, Munţiu A.

Bacteriol Virusol Parazitol Epidemiol. 1997 Jan-Jun;42(1-2):110-2. Romanian. No abstract available.

PMID:
9235136
15.

[Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].

Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.

Zhonghua Liu Xing Bing Xue Za Zhi. 2003 Jul;24(7):570-3. Chinese.

PMID:
12975010
16.

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.

Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y.

Vaccine. 2009 Jan 14;27(3):454-9. doi: 10.1016/j.vaccine.2008.10.077. Epub 2008 Nov 18.

PMID:
19022318
17.
18.

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, Weber F, Saville M.

J Infect Dis. 2008 Sep 1;198(5):650-8. doi: 10.1086/590434.

PMID:
18652550
19.

Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.

Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, Morag A, Zakay-Rones Z.

J Med Virol. 2001 Sep;65(1):178-84.

PMID:
11505461
20.

Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization.

Avtushenko SS, Sorokin EM, Zoschenkova NY, Zacharova NG, Naichin AN.

J Biotechnol. 1996 Jan 26;44(1-3):21-8.

PMID:
8717382

Supplemental Content

Support Center